Human conditions of insulin-like growth factor-I (IGF-I) deficiency

Table 2 Current proposed IGF-I treatments

Pathological condition	References
Laron Syndrome	[33–35, 200–208, 381–389, 397]
Liver cirrhosis	[219–234, 399]
Aging	[55, 56, 169, 245–248, 384]
IUGR	[37–41, 182–197]
Neurological disorders	[335, 336, 405–407]
Stroke	[337, 413]
Spinal cord injury	[421]
Cardiovascular protection	[270–277, 310, 415]
Diabetes	[302–306]
Insulin resistances/hyperinsulinism	[55, 404, 409, 423]
Metabolic syndrome	[301, 316]
Osteoporosis	[416, 417]
Cystic fibrosis	[408]
Wound healing	[410]
Myotonic dystrophy	[419]
AIDS muscle wasting	[411]
HIV-associated adipose redistribution syndrome	[411]
Burns	[299]
Crohn’s disease	[412]
Werner syndrome	[417]
X-linked severe combined immunodeficiency	[418]
Hearing loss prevention	[414]
Anorexia nervosa	[420]
Retinopathy of prematurity	[422]

rhIGF-I replacement therapy may be recommended only to restore IGF-I deficiency conditions. In consequence, despite the number of proposed pathological conditions that may benefit from rhIGF-I treatment, up to date, only those in the white have been well characterized. Conditions in clear grey are supported by a wide body of evidence which render these circunstances prone to be classified as the first group. Dark grey are conditions that may need more research in order to adequately propose the IGF-I treatment as a proper strategy.

ISSN: 1479-5876